Replies to post #3242 on Marker Therapeutics Inc (MRKR)

[Bio7mm]

I think TPIV stock could drift higher over the next two weeks in anticipation of the RS. Although converting the $5 million in debt on our books to common shares would dilute percent ownership, it would also create a much healthier balance sheet and eliminate investor uncertainty. It could cause a stock price increase. Look at how our stock price rose after June 29, 2009 when Wilson took over and they converted $3.2 million in debt to equity. The stock price rose! Capital raises also will dilute percent ownership but they can actually cause a stock price increase because they eliminate uncertainty and increase investor confidence when institutions buy in and show confidence in the company. Look at Arrowhead Research (ARWR) in the RNAi space and how the stock price rose after they issued more shares in capital raises in 2013! Having the cash to complete trials is key to Tapimmune experiencing significant value creation.